Showing 1421-1430 of 9428 results for "".
Advantages of More Topical Gel
https://practicaldermatology.com/series/pdt-in-practice/advantages-of-more-topical-gel/29176/Dr. Ashish Bhatia discusses increased dosing of a PDT photosensitizer for both lesion-directed and field-directed treatment of actinic keratosis.Evolving Perspectives: The Dermatology M&A Market in Today’s Environment
https://practicaldermatology.com/topics/practice-management/evolving-perspectives-the-dermatology-ma-market-in-todays-environment/23945/Halfway through 2023: The trends and emerging insights in the dermatology and aesthetics industries.DermWireTV: COVID Vaccine Approved; Update on Delta and Dermatology Practice
https://practicaldermatology.com/topics/practice-management/dermwiretv-covid-vaccine-approved-update-on-delta-and-dermatology-practice/19998/FDA approval of Pfizer-BioNTech’s Comirnaty COVID-19 Vaccine comes as Coronavirus case rates surge across the US. We take a look at potential implications for dermatology of the Delta variant spread.DermWireTV: Galderma Gets Cheeky, COVID Vax & Skin, AKN Classification
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-gets-cheeky-covid-vax-skin-akn-classification/19955/Only a small percentage of patients have skin reactions to COVID-19 vaccines, but true allergic reactions must be identified. FDA approves Restylane Contour from Galderma. New classification may aid treatment selection or acne keloidalis.Cash Savings Alternative: Increase Returns & Maintain Liquidity
https://practicaldermatology.com/topics/practice-management/cash-savings-alternative-increase-returns-maintain-liquidity--wnhimepo/18366/OJM Group Director of Financial Advisors Michael Lewellen, CFP provides an overview and financial example of a cash savings alternative that offers 100% liquidity while providing a higher return than traditional investment vehicles. Click here to request or download a free copy of Wealth ProtectionAesthetics: A European Perspective
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/aesthetics-a-european-perspective/18581/When it comes to cosmetic interventions, philosophies of beauty are similar are both sides of the Atlantic. But the tools to achieve aesthetic improvement are different. Dr. Sabine Zenker discusses what's different in Europe, including the availability of injection systems.AK Pearls: Managing Treatment Reactions
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-pearls-managing-treatment-reactions/18741/Dr. Bhatia shares pearls for managing side effects and reactions to actinic keratosis treatment drugs. There are many adjunctive therapies to counter these reactions from emollients to barrier repair cream to time and some TLC for patients.Robert Grant Steps Down at Alphaeon; Skin Cancer Special Edition
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-robert-grant-steps-down-at-alphaeon-skin-cancer-special-edition/18595/Robert Grant is no longer CEO of lifestyle healthcare company Alphaeon. Mr. Grant founded Alphaeon in 2013 as a wholly owned subsidiary of Strathspey Crown LLC, a private equity firm located in Newport Beach, CA, where he serves as Chairman. Also in this issue, a closer look at skin cancer. May is SDrug Prices Soar, Amgen Files BLA for Biosimilar to Humira
https://practicaldermatology.com/topics/practice-management/dermwiretv-drug-prices-soar-amgen-files-bla-for-biosimilar-to-humira/18672/In this edition, Amgen Submits ABP 501—first Adalimumab biosimilar; prices for dermatology drugs jump and a survey explores patient knowledge of antibiotic resistance. Also, Almirall acquires Veltin from Sitefel/GSK.Onexton Approved for Acne, Bellafill Debuts
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-onexton-approved-for-acne-bellafill-debuts/19019/In this edition of DermWireTV, from the editors of Practical Dermatology® magazine: Onexton is Valeant's fourth new approval in a year. We look at Suneva's renamed filler and the FDA's decision to grant breakthrough status to investigational atopic dermatitis treatment dupilumab. PLUS: This week's